Hexanohydroxamic Acid Derivatives for HDAC and HMGR Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors, such as lovastatin and suberoylanalide hydroxamic acid, are less effective in inhibiting cancer cell growth and can induce drug resistance, especially under hypoxic conditions, and have toxicity concerns.
Innovation Solution
Development of hexanohydroxamic acid derivative compounds like Lova-HA, Simva-HA, and Atorva-HA, which inhibit HDAC and/or HMGR activity more effectively with reduced toxicity and resistance, formulated as compounds of specific structures and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HDAC inhibitors (lovastatin, suberoylanalide hydroxamic acid) are used to inhibit cancer cell growth, then some antitumor activity is achieved, but drug resistance is induced especially under hypoxic conditions and toxicity occurs
Solution Approach 1:
The patent modifies the chemical structure of existing HDAC inhibitors by introducing hydroxamic acid derivatives with specific substitutions (e.g., Lova-HA, Simva-HA, Atorva-HA). These structural parameter changes enhance HDAC inhibition potency while reducing toxicity and preventing drug resistance, particularly under hypoxic conditions. The modified compounds achieve superior antitumor activity compared to parent compounds like lovastatin and suberoylanalide hydroxamic acid.
2Reliability
If HDAC inhibitors are used to treat cancer, then tumor suppressor gene expression can be restored, but the inhibitors show limited effectiveness in certain cancer types and conditions
Solution Approach 1:
The hexanohydroxamic acid derivatives are designed to function as multi-functional agents that inhibit both HDAC and HMGR enzymes. This dual inhibition mechanism provides broader efficacy across different cancer types and conditions, including hypoxic environments where traditional HDAC inhibitors fail. The compounds can restore tumor suppressor gene expression while maintaining effectiveness in various cancer contexts.
Solution Approach 2:
The patent combines functional elements from different inhibitor classes into a single hexanohydroxamic acid derivative structure. By integrating HDAC inhibition capability with HMGR inhibition capability in one molecule, the compound achieves enhanced versatility and effectiveness across multiple cancer types and physiological conditions, overcoming the limitations of single-target inhibitors.
3Reliability
If statins are used to inhibit HMGR for cholesterol reduction, then cardiovascular disease prevention is achieved, but additional antitumor activity and HDAC inhibition are not fully realized
Solution Approach 1:
The hexanohydroxamic acid derivatives maintain the HMGR inhibition capability of statins for cardiovascular protection while adding HDAC inhibition functionality. This multi-functionality allows the compounds to provide both cardiovascular disease prevention and antitumor activity, including cancer cell growth inhibition and tumor suppressor gene restoration, thereby expanding the therapeutic benefits beyond what conventional statins achieve.
Data Source
Figure 1(1A)~1(1B)
Figure 1(1C)~1(1D)
Figure 1(1E)~1(1F)
AI summary
The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.